Community Bank & Trust Waco Texas maintained its stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,650 shares of the pharmaceutical company’s stock at the end of the second quarter. Community Bank & Trust Waco Texas’ holdings in GlaxoSmithKline PLC were worth $548,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Cribstone Capital Management LLC acquired a new stake in GlaxoSmithKline PLC during the second quarter worth $117,000. Williams Jones & Associates LLC acquired a new stake in GlaxoSmithKline PLC during the first quarter worth $161,000. LS Investment Advisors LLC increased its stake in GlaxoSmithKline PLC by 167.5% in the second quarter. LS Investment Advisors LLC now owns 4,280 shares of the pharmaceutical company’s stock worth $185,000 after buying an additional 2,680 shares in the last quarter. Hutchinson Capital Management CA acquired a new stake in GlaxoSmithKline PLC during the first quarter worth $200,000. Finally, Cape Cod Five Cents Savings Bank acquired a new stake in GlaxoSmithKline PLC during the second quarter worth $201,000. Institutional investors own 8.79% of the company’s stock.
GlaxoSmithKline PLC (NYSE:GSK) traded up 0.54% on Friday, hitting $43.13. 2,588,026 shares of the company were exchanged. GlaxoSmithKline PLC has a 52-week low of $37.82 and a 52-week high of $45.58. The stock’s 50-day moving average price is $43.61 and its 200-day moving average price is $42.73. The stock has a market capitalization of $104.83 billion, a P/E ratio of 2695.62 and a beta of 0.85.
The company also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Friday, August 12th will be issued a dividend of $0.494 per share. The ex-dividend date is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 6,600.00%.
GSK has been the topic of a number of analyst reports. Citigroup Inc. upgraded shares of GlaxoSmithKline PLC from a “neutral” rating to a “buy” rating in a research note on Friday, July 1st. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, July 27th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 25th. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 24th. Finally, Piper Jaffray Cos. initiated coverage on shares of GlaxoSmithKline PLC in a research note on Friday, September 23rd. They set an “overweight” rating on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $47.86.
About GlaxoSmithKline PLC
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.